Cancer Blood Testing

TKcanine Cancer Panel - For the detection and therapeutic management of cancer in dogs with suspected or confirmed cancer.

Cancer is a common disease affecting dogs of all age, size & breed. The signs of cancer are often nondescript and can mimic many other types of diseases making the diagnosis of cancer challenging, often invasive and expensive. Once diagnosed, veterinarians have had few tools available to effectively monitor the course of treatment or disease progression.

TKCANINE CANCER PANEL has been clinically proven effective on a wide variety of tumor types. When a suspicious mass is identified, or the dog presents with other indicators common with cancer, the cancer panel is used to detect the presence of neoplastic disease.

TKCANINE CANCER PANEL combines the information obtained from two independent measures of cellular irregularity; abnormal cell division and systemic inflammation. Thymidine kinase type 1 (TK1) is a measure of dysregulated cellular proliferation - a hallmark of cancer. C-reactive protein (CRP) is elevated in the presence of systemic inflammatory disease. United through the Neoplasia Index (NI), the test panel provides objective evaluation for disease.

he panel is useful for monitoring treatment and disease progression. For patients undergoing therapy, results from the cancer panel can quickly indicate that the patient is responding to the treatment protocol, as indicated when both TK1 and CRP decline from the initial pretreatment assessment. With resistance to therapy, TK1 and CRP will be unresponsive and remain elevated. Upon disease recurrence, TK1 and CRP will elevate from baseline. Retesting intervals are recommended at 4-8 week intervals.

TKfeline Cancer Panel - For the differential diagnosis and monitoring of intestinal lymphosarcoma in cats.

Gastrointestinal disorders such as inflammatory bowel disease (IBD) and intestinal lymphoma (LSA) are commonly encountered in feline medicine. The challenge with these two similarly presenting diseases is how to quickly distinguish between the two.

TKFELINE CANCER PANEL combines the information obtained from two independent measures of cellular irregularity; abnormal cell division and systemic inflammation. Thymidine kinase type 1 (TK1) is a measure of dysregulated cellular proliferation – a hallmark of cancer. Haptoglobin (HPT) is elevated in the presence of systemic inflammatory disease. United through the Neoplasia Index (NI), the test panel provides objective evaluation for disease.

The panel is useful for monitoring treatment and disease progression. For patients undergoing therapy, results from the cancer panel can quickly indicate that the patient is responding to the treatment protocol, as indicated when both TK1 and HPT decline from the initial pretreatment assessment. With resistance to therapy, TK1 and HPT will be unresponsive and remain elevated. Upon disease recurrence, TK1 and HPT will elevate from baseline. Retesting intervals are recommended at 4-8 week intervals.

This information was taken directly from Veterinary Diagnostic Institute (VDI). For more information or to learn more, click here to be linked to their website.